- Line of prescribing revised to align with approvals of NICE technology appraisals
- Amended recommendation for prophylactic PRP noting it should be considered when regular follow-up is not possible, however, longitudinal studies on the efficacy of prophylactic PRP other than CVOS is limited
- Changes made to clarify the recommended treatment in patients with poor vision with significant macular oedema
- Amendment that macular oedema and neovascularisation of the retina (NVE) are the two major complications in the management of BRVO
- Amendment that the management of hemiretinal vein occlusion is similar to that described for central retinal vein occlusion
The scope of the guidelines is limited to current diagnostic tools, management and service set-up and delivery to facilitate delivery of optimal clinical care pathways and management for patients with RVO. The guidelines are prepared primarily for ophthalmologists; however, they are relevant to other healthcare professionals, service providers and commissioning organisations as well as patient groups. The guidelines do not cover rare, complex, complicated or unusual cases. It is recommended that readers refer to other relevant sources of information such as summaries of product characteristics (SPCs) for pharmaceutical products as well as the National Institute of Health and Care Excellence (NICE) and General Medical Council (GMC) guidance.